- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00644423
Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)
July 29, 2019 updated by: Durham VA Medical Center
Omega-3 Fatty Acids and PTSD
An increasing literature shows that omega-3 fatty acids provide numerous health benefits, including a variety of psychiatric symptoms and disorders including stress, anxiety, cognitive impairment, mood disorders (major depression and bipolar disorder) and schizophrenia.
Omega-3 fatty acids may additionally represent a promising treatment strategy in patients with PTSD.
Moreover, given its beneficial cardiovascular effects, adjunctive omega-3 fatty acids may also benefit the general health status of these veterans, who frequently present with a variety of comorbid medical disorders.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
See brief summary
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Durham VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Veterans 18-65 years of age, any ethnic group, either sex.
- Ability to participate fully in the informed consent process.
- Current diagnosis of PTSD .
- No anticipated need to alter medications for the 10-week duration of the study.
Exclusion Criteria:
- Serious unstable medical illness, history of traumatic brain injury (TBI) with loss of consciousness greater than 30 minutes, or history of cerebrovascular accident, prostate or breast cancer.
- Current active suicidal and/or homicidal ideation, intent or plan.
- Use of aspirin, warfarin or other anticoagulant therapy, as omega-3 fatty acids may increase bleeding time. Other concomitant medications for medical conditions will be addressed on a case-by-case base and determined if exclusionary.
- Regular use of omega-3 fatty acid supplementation within the last 3 months (cod liver oil, other fish oil, flaxseed).
- Regular consumption of more than one serving of fatty fish per week.
- Substance dependence within the last 4 weeks (other than nicotine dependence).
- Current Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition other than TBI.
- Female patients who are pregnant or breast-feeding.
- Known allergy to study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
Placebo
|
Matching Placebo
|
Active Comparator: 1
Omega-3 Fatty Acid
|
One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician-Administered PTSD Scale (CAPS)
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in posttraumatic stress disorder symptoms (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
Scores may range from 0 (no symptoms) to 136 (severe symptoms; score of 136 is based on the first 17 CAPS items administered).
A reduced CAPS score indicates a reduction in (improvement) PTSD symptoms, while an increase in CAPS score indicates an increase (worsening) in PTSD symptoms.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Brief Assessment of Cognition in Affective Disorders (BAC-A)
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores to assess cognitive changes (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
The BAC-A includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed.
Z-scores are calculated from composite scores.
Higher z-scores are indicative of better cognitive performance, lower z-scores are indicative of lower cognitive performance.
Range of z-scores anticipated to be between -3 and 3. Mean change scores from week 2 and week 10 (Week 2 minus Week 10).
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quick Inventory of Depressive Symptomatology (QIDS)
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in depressive symptomatology (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
The QIDS total scores range from 0 to 27.
Total score is obtained by adding the scores for each of the nine symptom domains of the DSM-IV Major Depressive Disorder (MDD) criteria: depressed mood,loss of interest or pleasure,concentration/decision making,self-outlook,suicidal ideation, energy/fatigability, sleep,weight/appetite change, and psychomotor changes.
Each item is rated 0-3 (0=least or no severity, 3=greatest severity).
Higher values reflect more severe symptoms.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Connor Davidson Resilience Scale (CD-RISC)
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in resiliency (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
The CD-RISC was developed and tested as (i) a measure of degree of resilience, (ii) as a predictor of outcome to treatment with medication or psychotherapy, stress management and resilience-building, (iii) as a marker of progress during treatment, and (iv) as a marker of biological changes in the brain.
The scale comprises 25 items, each rated on a 5-point scale (0-4) for a total range of 0-100, with higher scores reflecting greater resilience.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Continuous Performance Test (CPT)
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in inpulsivity (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
Computer test.
Patient is to press button if target appears, but not at non-target.
Impulsivity variables during test: CE=percent of response to non-target; ANT=percent of responses prior to target presentation.
Results are converted to Q-scores (age and sex-adjusted normalized scores with a mean=0 and standard deviation=1 in the general population, expressing the probability determined by the Gamma function in terms of standard deviation of Gaussian density).
Higher scores reflect more severe symptoms.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Trail Making A
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in cognition and attention (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
Trail Making Test is a measure used to assess cognition and attention.
Trail Making, Part A is a timed test that consists of 25 circles on a piece of paper with the numbers 1-25 written randomly in circles.
The respondent is asked to draw a line from number one, and so on, in correct numerical order, until they reach number 25. Results are reported as the number of seconds required to complete the task.
Higher scores indicate greater impairment.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Trail Making B
Time Frame: Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Mean change scores in attention and cognition (Week 10 (Week 8 Post-Randomization) minus Week 2 (Baseline)).
Trail Making Test is a measure used to assess cognition and attention.
Trail Making, Part B is a timed test that consists of 25 circles on a piece of paper with both numbers (1 - 13) and letters (A - L); the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.).
The respondent is asked to draw a line from number one, and so on,in correct numerical/alphabetical order, until they reach number 13. Results are reported as the number of seconds required to complete the task.
Higher scores indicate greater impairment.
|
Week 2 (Baseline) and Week 10 (Week 8 Post-Randomization)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christine E Marx, MD,MA, Durham VA Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2008
Primary Completion (Actual)
July 15, 2010
Study Completion (Actual)
July 15, 2010
Study Registration Dates
First Submitted
March 20, 2008
First Submitted That Met QC Criteria
March 25, 2008
First Posted (Estimate)
March 26, 2008
Study Record Updates
Last Update Posted (Actual)
August 20, 2019
Last Update Submitted That Met QC Criteria
July 29, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VA IRB# 01210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Posttraumatic Stress Disorder
-
University Hospital, ToursCompletedPostTraumatic Stress DisorderFrance
-
The University of Texas Health Science Center at...University of Pennsylvania; Brooke Army Medical Center; C.R.Darnall Army Medical... and other collaboratorsCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Icahn School of Medicine at Mount SinaiCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Berlin Center for the Treatment of Torture VictimsCompletedPosttraumatic Stress Disorder (PTSD)Germany
-
TEMPVA Research Group, Inc.C.R.Darnall Army Medical Center; VA Boston Healthcare System; Central Texas Veterans...UnknownPosttraumatic Stress Disorder, Combat-relatedUnited States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
-
Yale UniversityNational Center for PTSDCompletedPosttraumatic Stress Disorder (PTSD)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States